Soft tissue sarcomas (STS) are a rare group of malignant heterogenous tumors (> 50
histological subtypes, including liposarcoma, the commonest subtype of STS) with distinct
genetic, pathological and clinical profiles, and varying patterns of tumor spread. The
optimal cytotoxic treatment for this group of patients remains uncertain. Single agents which
are most effective include doxorubicin and ifosfamide, but objective response rates and
progression-free survival times remain modest. There is clearly a need to improve treatment
options for liposarcoma. Eribulin, a antimicrotubule agent that targets the protein tubulin
in cells, interfering with cancer cell division and growth , has demonstrated activity in
STS. Therefore, it is reasonable to explore whether other anti-microtubule agent like
cabazitaxel have a role in STS. Cabazitaxel has been shown to be a relatively safe, effective
and tolerated. This drug has been approved by FDA for prostate cancer. The main objective of
this trial is to determine whether cabazitaxel demonstrate sufficient antitumor activity for
liposarcoma.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC